Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Dara-vd vs vrd: A breakthrough in newly diagnosed multiple myeloma treatment — superior survival and safety profiles

Huinan Jiang, Xianming He, Xuelin Dou et al. Nov 03, 2025 pp. 7583-7583 10.1182/blood-2025-7583

Abstract Effective induction regimens are critical for improving outcomes in newly diagnosed multiple myeloma (NDMM). Bortezomib, lenalidomi...

Zanubrutinib plus R-CHOP versus R-CHOP as first-line therapy in double-expressor DLBCL: A multicenter, propensity score matched retrospective study

Yi Xia, Qingqing Cai, Dongyu Zhuang et al. Nov 03, 2025 pp. 7202-7202 10.1182/blood-2025-7202

Abstract Background: Double-expressor diffuse large B-cell lymphoma (DE-DLBCL), characterized by MYC and BCL2 protein overexpression without...

Protein arginine methyltransferase 1 is required for megakaryocyte-mediated inflammatory response

Peipei Zhang, Anlun Li, Szumam Liu et al. Nov 03, 2025 pp. 6579-6579 10.1182/blood-2025-6579

Abstract Background: Megakaryocytes (MKs) are heterogeneous, with one subgroup known as immune MKs, which express immune regulatory transcri...

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Christine Riedhammer, Marietta Truger, Holly Lee et al. Nov 03, 2025 pp. 5785-5785 10.1182/blood-2025-5785

Abstract Introduction: No other hematologic malignancy has seen more drug approvals than multiple myeloma (MM). Yet, MM remains largely incu...

In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant

Grace Birch, Juliana Vergara-Cadavid, Alba Martini et al. Nov 03, 2025 pp. 261-261 10.1182/blood-2025-261

Abstract Introduction/Background: Minimal residual disease (MRD) negative complete response portends better prognosis in multiple myeloma (M...

Clinical and demographic characteristics of MYH9-related disorders patients: A comprehensive analysis of 16 cases from a single center

Alfadil Haroon, Maha Aljasser, Maddirevula Sateesh et al. Nov 03, 2025 pp. 1252-1252 10.1182/blood-2025-1252

Abstract Introduction: MYH9-related disorders are rare inherited platelet disorders which are characterized by macrothrombocytopenia with or...

Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis

Usman Ilyas, Carolyn Mead-Harvey, Yenny Moreno Vanegas et al. Nov 03, 2025 pp. 6016-6016 10.1182/blood-2025-6016

Abstract Background In patients with myelofibrosis (MF) undergoing allogeneic hematopoietic cell transplantation (allo-HCT), graft-versus-ho...

Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma

Helen Gandler, Rashmi Khanal, Christina Darwish et al. Nov 03, 2025 pp. 5506-5506 10.1182/blood-2025-5506

Abstract Introduction - Chimeric antigen receptor (CAR) T cell therapy has become a highly effective salvage option for patients with relaps...

Post-operative thrombocytopenia in on- versus off-pump coronary artery bypass grafting

Thomas Fusillo, Kyle Reichard, Brett Sherman et al. Nov 03, 2025 pp. 3028-3028 10.1182/blood-2025-3028

Abstract Background: Thrombocytopenia is a common post-operative finding in major surgeries including coronary artery bypass grafting (CABG)...

Development of predictive relapse indicators for myeloma T cell engagers (PRIME) model for myeloma patients receiving BCMA- and GPRC5D-targeting T cell engagers

Tarek Mouhieddine, Tianxiang Sheng, Junia Vieira et al. Nov 03, 2025 pp. 3996-3996 10.1182/blood-2025-3996

Abstract Introduction: T cell engagers (TCEs), particularly those targeting B-cell maturation antigen (BCMA) and G-protein coupled receptor c...

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

Kuo-Kai Chin, Brian Ball, Yasmin Abaza et al. Nov 03, 2025 pp. 39-39 10.1182/blood-2025-39

Abstract Introduction: Menin is essential for leukemogenesis in KMT2A-rearranged (KMT2Ar) and Nucleophosmin 1-mutated (NPM1c) AML. Menin inh...

Error-corrected sequencing to quantify clonal hematopoiesis in breast cancer survivors treated with metformin in a randomized, placebo controlled, prospective clinical trial

Zhan Rong, Soo Park, Laura Tennis et al. Nov 03, 2025 pp. 4954-4954 10.1182/blood-2025-4954

Abstract BACKGROUND: Targeting clonal hematopoiesis (CH) in an interventional clinical study involves significant challenges including: a la...

Dose Escalation shows no benefit compared to continuing ABVD in Hodgkin's lymphoma patients with an interim PET deauville score of 4

Paloma Resende, Andre Meireles, Wysterlanyo Kayo Barros et al. Nov 03, 2025 pp. 1854-1854 10.1182/blood-2025-1854

Abstract Introduction: Interim Fluorodeoxyglucose positron emission tomography (PET) conducted in patients with classic Hodgkin's Lymphoma (...

Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL

Laura Fogliatto, Ana Cordeiro, Eva Domingo Domenech et al. Nov 03, 2025 pp. 5349-5349 10.1182/blood-2025-5349

Abstract Background: Anti-CD20 antibodies like rituximab are crucial for treating non-Hodgkin's B-cell lymphoma. However...

EB2023 primes mitochondria for BCL2 dependence and induces pyroptotic cell death via AMPK signaling and the unfolded protein response

Matthew Villaume, Michael Davidson, Anna Skwarska et al. Nov 03, 2025 pp. 637-637 10.1182/blood-2025-637

Abstract The F1 catalytic domain of ATP synthase performs the final and pivotal step of oxidative phosphorylation (OXPHOS). EB2023 is a sele...

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Wei Liu, Chen Huang, Xiaojing Yan et al. Nov 03, 2025 pp. 1919-1919 10.1182/blood-2025-1919

Abstract Background: Platinum-based salvage chemotherapy is the most widely used treatment approach for relapsed or refr...

Dysregulation of the complement system in immune thrombocytopenia

Justin Oosterlee, Norá Veszeli, Jasmin Sabrina Rast et al. Nov 03, 2025 pp. 4823-4823 10.1182/blood-2025-4823

Abstract Background Primary immune thrombocytopenia (ITP) is a rare acquired autoimmune disease characterised by a destruction and impaired...

Ven+FluBu2 with ptcy/tac/MMF RIC transplant followed by venetoclax/azacitidine maintenance for high-risk MDS/AML

H. Moses Murdock, Kyle Hebert, Jennifer Brock et al. Nov 03, 2025 pp. 4206-4206 10.1182/blood-2025-4206

Abstract Background: We previously demonstrated that incorporating venetoclax (Ven) into reduced intensity conditioning (RIC) chemotherapy f...

Randomized comparison of ponatinib versus imatinib in combination with chemotherapy in patients 55 years of age and older with newly diagnosed ph+ ALL: Molecular response and initial outcome analysis of the EWALL PH03 Study

Oliver Ottmann, Tongtong Shi, Kimmo Porkka et al. Nov 03, 2025 pp. 440-440 10.1182/blood-2025-440

Abstract BCR :ABL1 tyrosine kinase inhibitors (TKIs) plus reduced intensity chemotherapy are considered standard of care for older patients (...

IDH2 R172 mutation is associated with improved survival in IDH-mutated AML/MDS patients undergoing allogeneic stem cell transplantation: A geth-TC multicenter study

Ana Perez Gonzalez, Víctor Navarro Garces, Manuel Guerreiro et al. Nov 03, 2025 pp. 6082-6082 10.1182/blood-2025-6082

Abstract Introduction: Mutations in isocitrate dehydrogenase (IDH1 and IDH2) occur in approximately 15–20% and 5-15% of AML and MDS patients...

Incidence of cardiac events associated with next-generation bruton tyrosine kinase (BTK) inhibitors compared to control in hematologic malignancies: A meta-analysis of randomized trials

Ramaditya Srinivasmurthy, Abbas Hussain, Rishi Nanda et al. Nov 03, 2025 pp. 8067-8067 10.1182/blood-2025-8067

Abstract Background: Bruton tyrosine kinase inhibitors (BTKi) have revolutionized the treatment of B-cell malignancies b...

Correlation of flow cytometry ogata score with cytogenetic abnormalities in myelodysplastic syndromes.

Elizabeth Souto, Laiz Bento, Daniela Borri et al. Nov 03, 2025 pp. 7380-7380 10.1182/blood-2025-7380

Abstract Background and Aims: Flow cytometry (FCM) is a fast valuable tool for detecting dysplasia in the diagnosis of MDS, with Ogata score...

Two decades of pregnancy outcomes in women with CML: Insights from a real-world single-center cohort

Sadashivudu Gundeti, Stalin Chowdary Bala, Meher Lakshmi Konatam et al. Nov 03, 2025 pp. 3789-3789 10.1182/blood-2025-3789

Abstract Background: The advent of tyrosine kinase inhibitors (TKIs) has transformed Chronic Myeloid Leukemia (CML) from a fatal disease into...

Immune reconstitution with the use of bruton tyrosine kinase inhibitor treatment for patients with Waldenstrom's macroglobulinemia

Tanim Jain, Nisha Hariharan, Benjamin Heyman Nov 03, 2025 pp. 7105-7105 10.1182/blood-2025-7105

Abstract Waldenstrom's macroglobulinemia (WM) is a rare B-cell lymphoma defined by immunoglobulin (Ig) M monoclonal gammopathy and lymphopla...

A comparative analysis of efficacy results in clinical trial publications and US prescribing information demonstrates a high degree of discordance in reported response endpoints for Acute Myeloid Leukemia

Mansi Dalal, Donna Przepiorka Nov 03, 2025 pp. 5229-5229 10.1182/blood-2025-5229

Abstract The efficacy results in clinical trial publications inform medical practice, build a reliable knowledge base, and provide statistic...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page